Cargando…

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study

BACKGROUND: Dose escalation of biologics may regain treatment response in patients with ulcerative colitis (UC). However, dose escalation rates and associated outcomes and costs are not well characterized in biologic-naïve patients receiving antitumor necrosis factor-alpha (anti–TNF-α) treatments, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosh, Sabyasachi, Kathe, Niranjan, Umashankar, Kandavadivu, Mirchandani, Kirti, Hait, Arunima, Paul, Riyanka, Candela, Ninfa, Fan, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653026/ https://www.ncbi.nlm.nih.gov/pubmed/38028955 http://dx.doi.org/10.1093/crocol/otad061

Ejemplares similares

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Odessa
por: Forsyth, Frederick, 1938-
Publicado: (1973)

Odessa
por: Forsyth, Frederick, 1938-
Publicado: (1975)

The Odessa file /
por: Forsyth, Frederick
Publicado: (1973)

Wolfgang Pauli in Odessa
por: Unknown
Publicado: (1930)

Wolfgang Pauli in Odessa
por: Unknown
Publicado: (1930)

Wolfgang Pauli in Odessa
por: Unknown
Publicado: (1930)

The Jews of Odessa : a cultural history, 1794-1881 /
por: Zipperstein, Steven J., 1950-
Publicado: (1986)

Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
por: Benson, Rosalind, et al.
Publicado: (2020)

Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results
por: Hyams, Jeffrey S, et al.
Publicado: (2020)

Economic outcomes associated with diagnosed behavioral symptoms among patients with dementia in the United States: a health care claims database analysis
por: Khandker, Rezaul Karim, et al.
Publicado: (2023)

Diagnosis of behavioral symptoms as a predictor of institutionalization among Medicaid patients with dementia
por: Khandker, Rezaul Karim, et al.
Publicado: (2023)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Manoscritto da odessa : nuovi racconti e saggi ritrovati nella citta natale dello sctittore
por: Babelʹ, I. 1894-1940 (Isaak)

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Partners of patients with ulcerative colitis exhibit a biologically relevant dysbiosis in fecal microbial metacommunities
por: Chen, Guang-Lan, et al.
Publicado: (2017)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
por: Sfikakis, Petros P., et al.
Publicado: (2023)

Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
por: Hunter, Theresa, et al.
Publicado: (2022)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn’s Disease
por: Chanchlani, Neil, et al.
Publicado: (2023)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Risk network approaches to locating undiagnosed HIV cases in Odessa, Ukraine
por: Smyrnov, Pavlo, et al.
Publicado: (2018)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
por: Long, Millie D., et al.
Publicado: (2022)

Social network approaches to locating people recently infected with HIV in Odessa, Ukraine
por: Williams, Leslie D, et al.
Publicado: (2019)

Human Papillomavirus Type 16 Circular RNA Is Barely Detectable for the Claimed Biological Activity
por: Yu, Lulu, et al.
Publicado: (2022)

The Hypercomplex Genome of an Insect Reproductive Parasite Highlights the Importance of Lateral Gene Transfer in Symbiont Biology
por: Frost, Crystal L., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Kobayashi, Taku, et al.
Publicado: (2023)

Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn’s Disease
por: Siegel, Corey A, et al.
Publicado: (2021)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis
por: Fredrick, Thomas W, et al.
Publicado: (2022)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Anti-ulcerogenic and anti-ulcerative colitis (UC) activities of seven amines derivatives
por: Awaad, Amani S., et al.
Publicado: (2017)

Prevalence of Intestinal Protozoan Infection in Patients with Ulcerative Colitis (UC) in Isfahan, Iran
por: Pestechian, Nader, et al.
Publicado: (2021)

Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1nq31p6t11o1g29kld3v5fm4u